Hepatitis C Virus Resistance-Associated Substitutions in Mexico

被引:0
作者
Jose-Abrego, Alexis [1 ,2 ]
Laguna-Meraz, Saul [1 ,2 ]
Roman, Sonia [1 ,2 ]
Mariscal-Martinez, Irene M. [1 ,2 ,3 ]
Panduro, Arturo [1 ,2 ]
机构
[1] Civil Hosp Guadalajara Fray Antonio Alcalde, Dept Genom Med Hepatol, Guadalajara 44280, Mexico
[2] Univ Guadalajara, Hlth Sci Ctr, Guadalajara 44340, Mexico
[3] Univ Guadalajara, Hlth Sci Ctr, Doctoral Program Mol Biol Med, Guadalajara 44340, Jalisco, Mexico
来源
VIRUSES-BASEL | 2025年 / 17卷 / 02期
关键词
hepatitis C virus; subtype; antiviral resistances; NS3/4A PROTEASE INHIBITOR; TREATMENT-NAIVE PATIENTS; GENOTYPE; INFECTION; DIRECT-ACTING ANTIVIRALS; HCV NS5A INHIBITOR; IN-VITRO; PLUS RIBAVIRIN; OPEN-LABEL; RECEIVING DACLATASVIR; PEGYLATED INTERFERON;
D O I
10.3390/v17020169
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Hepatitis C virus (HCV) is susceptible to resistance-associated substitutions (RASs) in the NS3, NS5A, and NS5B nonstructural genes, key targets of the direct-acting antivirals (DAAs). This study aimed to assess the prevalence and distribution of RASs across different HCV subtypes in Mexico. A Genbank dataset of 566 HCV sequences was analyzed. Most sequences were from Mexico City (49.1%, 278/566) and Jalisco (39.4%, 223/566). The NS5B region was the most sequenced (59.7%, 338/566). The most frequent HCV subtypes were 1a (44.0%, 249/566), 1b (28.6%, 162/566), 2b (9.5%, 54/566), and 3a (6.2%, 35/566). Subtypes 1a (57.4%, 128/223) and 3a (12.6%, 28/223) were significantly higher in Jalisco than in Mexico City (34.2%, 95/278 and 2.5%, 7/278), whereas subtype 1b was higher in Mexico City (34.5%, 96/278 vs. 14.8%, 33/223). Subtype 1a increased from 2019 to 2024, representing 49.4% (123/249) of all reported cases. RASs were detected in NS3 (6.7%, 1/15), NS5A (2.9%, 3/102), and NS5B (0.3%, 1/349), with the most frequent mutations being Q80K, Y93H, and S282T, respectively, and detected in subtypes 1b (n = 3), 1a (n = 1), and 2a (n = 1). In conclusion, Mexico's HCV sequencing-based surveillance is limited. Subtype 1a predominated, but frequencies varied across states. The prevalence of RASs varied by gene from 0.3% to 6.7%. Establishing regional sequencing centers for NS3, NS5A, and NS5B is crucial to monitoring Mexico's DAA-resistant mutations and HCV subtype genetic diversity.
引用
收藏
页数:17
相关论文
共 128 条
[1]   Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection [J].
Afdhal, Nezam ;
Zeuzem, Stefan ;
Kwo, Paul ;
Chojkier, Mario ;
Gitlin, Norman ;
Puoti, Massimo ;
Romero-Gomez, Manuel ;
Zarski, Jean-Pierre ;
Agarwal, Kosh ;
Buggisch, Peter ;
Foster, Graham R. ;
Braeu, Norbert ;
Buti, Maria ;
Jacobson, Ira M. ;
Subramanian, G. Mani ;
Ding, Xiao ;
Mo, Hongmei ;
Yang, Jenny C. ;
Pang, Phillip S. ;
Symonds, William T. ;
McHutchison, John G. ;
Muir, Andrew J. ;
Mangia, Alessandra ;
Marcellin, Patrick .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) :1889-1898
[2]   Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6 [J].
Angel Patino-Galindo, Juan ;
Salvatierra, Karina ;
Gonzalez-Candelas, Fernando ;
Xavier Lopez-Labrador, F. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (04) :2402-2416
[3]  
[Anonymous], 1995, EMA
[4]   Presence of rare hepatitis C virus subtypes, 2j, 2k, and 2r in Mexico City as identified by sequencing [J].
Antonio Uribe-Noguez, Luis ;
Ocana-Mondragon, Alicia ;
Antonio Mata-Marin, Jose ;
Elena Gomez-Torres, Maria ;
Maria Ribas-Aparicio, Rosa ;
de la Luz Martinez-Rodriguez, Maria .
JOURNAL OF MEDICAL VIROLOGY, 2018, 90 (07) :1277-1282
[5]  
Asante-Appiah E, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00363-17, 10.1128/aac.00363-17]
[6]   An overview of HCV molecular biology, replication and immune responses [J].
Ashfaq, Usman A. ;
Javed, Tariq ;
Rehman, Sidra ;
Nawaz, Zafar ;
Riazuddin, Sheikh .
VIROLOGY JOURNAL, 2011, 8
[7]   Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors [J].
Bae, Andrew ;
Sun, Siu-Chi ;
Qi, Xiaoping ;
Chen, Xiaowu ;
Ku, Karin ;
Worth, Angela ;
Wong, Kelly A. ;
Harris, Jeanette ;
Miller, Michael D. ;
Mo, Hongmei .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (12) :5288-5297
[8]   Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies [J].
Barnard, Richard J. O. ;
Howe, John A. ;
Ogert, Robert A. ;
Zeuzem, Stefan ;
Poordad, Fred ;
Gordon, Stuart C. ;
Ralston, Robert ;
Tong, Xiao ;
Sniukiene, Vilma ;
Strizki, Julie ;
Ryan, Desmond ;
Long, Jianmin ;
Qiu, Ping ;
Brass, Clifford A. ;
Albrecht, Janice ;
Burroughs, Margaret ;
Vuocolo, Scott ;
Hazuda, Daria J. .
VIROLOGY, 2013, 444 (1-2) :329-336
[9]  
Belaunzaran-Zamudio PF, 2017, AIDS RES HUM RETROV, V33, P524, DOI [10.1089/aid.2016.0271, 10.1089/AID.2016.0271]
[10]   DDX3X inhibitors, an effective way to overcome HIV-1 resistance targeting host proteins [J].
Brai, Annalaura ;
Riva, Valentina ;
Saladini, Francesco ;
Zamperini, Claudio ;
Trivisani, Claudia Immacolata ;
Garbelli, Anna ;
Pennisi, Carla ;
Giannini, Alessia ;
Boccuto, Adele ;
Bugli, Francesca ;
Martini, Maurizio ;
Sanguinetti, Maurizio ;
Zazzi, Maurizio ;
Dreassi, Elena ;
Botta, Maurizio ;
Maga, Giovanni .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 200